A tale of three species – rabbits,chickens and humans: an interview with clinical trials pioneer Jeremiah Stamler

1. Figurovskii NA , Solov’ev YI . Alexander Porfire’vich Borodin: a chemist’s biography (in Russian). Springer-Verlag, 1950 [comment from JW: Borodin the chemist is the same Borodin who was the famous composer].

2. Anitschkow N . Experimental arteriosclerosis in animals. In Cowdry EV ed. Arteriosclerosis: a survey of the problem. Macmillan, 1933: 271–322.

3. Finking G , Hanke H . Nikolaj Nikolajewitsch Anitschkow (1885–1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis 1997; 135: 1–7.

4. Stamler J . Established major coronary risk factors: historical overview. In Marmot M , Elliott P eds. Coronary heart disease epidemiology: from aetiology to public health, 2nd edition. Oxford University Press, 2005: 18–31.

5. Pick R , Stamler J , Rodbard S , Katz LN . Inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation 1952; 6: 276–280.

6. Stamler J , Pick R , Katz LN . Inhibition of cholesterol induced coronary atherogenesis in the egg producing hen. Circulation 1954; 10: 251–254.

7. Rossouw JE , Anderson GL , Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

8. Anderson GL , Limacher M , Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712.

9. Stamler J , Pick R , Katz LN et al. Effectiveness of estrogen for therapy of myocardial infarction in middleage men. JAMA 1963; 183: 632–638.

10. Cox RL , Crawford ED . Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991–1998.

11. Tyler ET . Eight years’ experience with oral contraception and an analysis of use of low-does norethisterone. Br Med J 1964; 5413: 834–837.

12. Fisher RL .Design of experiments (originally published in 1935), 8th edition. Hafner, 1996.

13. Farinaro E , Stamler J , Upton M et al. Plasma glucose levels: long-term effect of diet in the Chicago Coronary Prevention Evaluation Program. Ann Int Med 1977; 86: 147–154.

14. Knowler WC , Barrett-Connor E , Fowler SE et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

15. The Multiple Risk Factor Intervention Trial Group . Statistical design considerations in the NHLI multiple risk factor intervention trial (MRFIT). J Chronic Dis 1977; 30: 261–275.

16. Katz LN , Stamler J .Experimental atherosclerosis. Charles C. Thomas, 1953.

17. Stamler J , Stamler R , Neaton JD et al. Low risk factor profile and long-term cardiovascular and non-cardiovascular mortality and life expectancy: findings for five large cohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012–2018.

18. Greenland P , Knoll MD , Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891–897.

19. U.S. Department of Health Education and Welfare (DHEW) . Smoking and health. Report of the Advisory Committee to the Surgeon General. U.S. Government Printing Office, 1964.

20. Hill AB .Principles of medical statistics. Oxford University Press, 1937.

21. Lampton L . “Goldberger’s War” in Mississippi: the 1915 Pellagra Experiment at Rankin State Farm and a new book. J Miss State Med Assoc 2005; 46: 44–47.

22. Pierce JR . “In the interest of humanity and the cause of science”: the yellow fever volunteers. Mil Med 2003; 168: 857–863.

23. Stamler J . On the natural history of hypertension and hypertensive disease. In Cort JH , Fencl V , Hejl Z , Jirka J eds. The pathogenesis of essential hypertension: proceedings of the Prague Symposium. State Medical Publishing House, 1960: 67–74.

24. Stamler J . On the epidemiology of hypertensive disease. In Cort JH , Fencl V , Hejl Z , Jirka J eds. The pathogenesis of essential hypertension: proceedings of the Prague Symposium. State Medical Publishing House, 1960: 107–110.

25. Stamler J .Lectures on preventive cardiology. Grune and Stratton, 1967.

26. Committee of Principal Investigators . Report of a cooperative trial on primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069–1118.

27. Canner PL , Berge KG , Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–1255.

28. Coronary Drug Project Research Group . Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038–1041.

29. Prout TE , Knatterud GL , Meinert CL , Klimt CR .The UGDP controversy. Clinical trials versus clinical impressions. Diabetes 1972; 21: 1035–1040.

30. Multiple Risk Factor Intervention Trial Research Group . Multiple Risk Factor Intervention Trial—risk factor changes and mortality results. JAMA 1982; 248: 1465–1477.

31. Gotto AM, Jr. The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. JAMA 1997; 277: 595–597.

32. Stamler J , Wentworth D , Neaton JD . Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–2828.

33. Neaton JD , Kuller L , Stamler J , Wentworth DN .Impact of systolic and diastolic blood pressure on cardiovascular mortality. In Laragh JH , Brenner BM eds. Hypertension: physiology, diagnosis, and management, 2nd edition. Raven Press, 1995: 127–144.

34. Stamler J , Stamler R , Garside D et al. Socioeconomic status cardiovascular risk factors, and cardiovascular disease: findings on US working populations. In, Report of the Conference on Socioeconomic Status and Cardiovascular Health and Disease 6–7. Nov, 1995. National Heart, Lung, and Blood Institute 1996: 109–118.

35. Davey Smith G , Neaton JD , Wentworth D , Stamler R , Stamler J . Morality differences between black and white men in the USA – contribution of income and other risk factors among men screened for the MRFIT. Lancet 1998; 351: 934–939.

36. Elliott P , Stamler J . Commentary: Evidence on salt and blood pressure is consistent and persuasive. Int J Epidemiol 2002; 31: 316–319.

37. Vaccaro O , Eberly LE , Neaton JD et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004; 164: 1438–1443.

38. Stamler J , Elliott P , Dennis B et al. INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary). J Hum Hypertens 2003; 17: 591–608.

39. Stamler J . The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nut 1997; 65: 626S–642S.

40. Stamler J , Neaton J , Garside D , Daviglus M .Current status: six established major risk factors – and low risk. In Marmot M , Elliott P eds. Coronary heat disease epidemiology: from aetiology to public health, 2nd edition. Oxford University Press, 2005: 32–70.

41. Stamler J , Elliott P , Dyer AR et al. Commentary: Sodium and blood pressure in the Intersalt study and other studies – in reply to the Salt Institute. Br Med J 1996; 312: 1285–1287.

42. Miura K , Daviglus ML , Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: The Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161: 1501–1508.

43. Rifkind BM . Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am J Cardiol 1984; 54: 30C–34C.